Investors Can Take Lead in Inovio Pharmaceuticals Securities Fraud Lawsuit

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) investors are urged to take action regarding a securities fraud lawsuit. The Rosen Law Firm, a renowned global investor rights law firm, is reminding individuals who purchased Inovio securities between October 10, 2023, and December 26, 2025, of the imminent April 7, 2026 lead plaintiff deadline.

Investors who acquired Inovio securities during the specified Class Period may have rights to compensation without incurring any upfront fees or costs due to a contingency fee arrangement. To participate in the Inovio class action, interested parties can visit the Rosen Law Firm’s website or contact Phillip Kim, Esq. via phone or email for more information on the class action proceedings. It’s important to note that a class action lawsuit has already been initiated, and those looking to act as lead plaintiff must submit their claims before the April 7, 2026, deadline. A lead plaintiff serves as a representative party on behalf of other class members to oversee the litigation process.

The Rosen Law Firm recommends that investors choose legal representation with a proven track record in leadership positions when navigating securities-related matters. Often, firms issuing legal notices may lack the necessary experience, resources, or industry recognition compared to established legal entities like the Rosen Law Firm. Some organizations that distribute notices may not directly handle securities class actions but instead act as intermediaries that refer clients to other law firms for litigation services. Therefore, it’s crucial to make informed decisions when selecting legal counsel for matters related to securities law.

The Rosen Law Firm specializes in representing investors worldwide, focusing primarily on securities class actions and shareholder derivative litigation. The firm has a history of securing significant settlements, including the largest securities class action settlement at the time against a Chinese company. Investors are encouraged to partner with experienced legal professionals who can provide effective guidance and representation in navigating complex securities fraud cases successfully.